From the publishers of JADPRO

CAR T-Cell Therapy Resource Center

Advertisement

Comparison of 2-Year Outcomes With CAR T Cells (ZUMA-1) Versus Salvage Chemotherapy in Refractory Large B-Cell Lymphoma

A 2-year analysis confirmed a substantially higher objective response rate and a 73% reduction in risk of death with axicabtagene ciloleucel compared with standard salvage regimens for patients with refractory large B-cell lymphoma.

Blood Advances
Advertisement
News & Literature Highlights
Advertisement
Advertisement